22KIT
raise HbA1c and increase risk of diabetes complications.
CeQur Simplicity encourages adherence and has shown
to reduce A1C to less than 7% and increase time-in-range
by 50%. We will be keeping an eye on the development
of this technology as it seems to have relevance to both
people with Type 1 and Type 2 diabetes. It is designed to
be worn for 3 days, and you dose direct from the patch.
www.myceqursimplicity.com
Dexcom
Dexcom Chair, President & CEO Kevin Sayer, presented
clinical study results for it's soon-to-launch CGM, the G7
at the 40th Annual J.P. Morgan Healthcare Conference
in January 2022. "The performance of this product is
something I never really thought I would see in nearly 30
years in this business," Sayer said during his J.P. Morgan
presentation.
G7 features a 60% size reduction from the G6, a
30-minute warmup period, more information in one place
with personalized insights, extended-wear design and
more.
Data presented by Sayer and Dexcom highlighted
strong performance to accompany the new and
improved features of the next-generation technology. G7
outperformed ICGM standards established by the FDA
across the board with its time-in-range performance,
including overall time-in-range (measured by percentage
within 20%) with a tally of 93.3% compared to the FDA
standard of 87%.
Mean absolute relative difference (MARD) for G7
registered at 8.1% in paediatric patients and 8.2% in
adult patients, highlighting consistency to accompany
performance.
"G7 very comfortably meets high CGM standards,"
Sayer said. "This dataset is three times larger than our G6
data set and much larger than any data set anybody else
has ever produced in the industry. With a sample size this
large, there's absolutely no doubt as to how the system
will perform. The results are much superior to G6 and any
competitor product in the market."
www.dexcom.com/en-GB
Medtronic
Ali Dianaty, vice president of product innovation
and operations for Medtronic Diabetes has said that
the diabetes group is focusing on new products and
strategies to keep up with the constantly growing
competition in both the CGM and insulin pump markets.
New focuses include developing an insulin pump patch
product to compete with Insulet and, eventually, Tandem,
as well as investing in direct-to-consumer advertising as
the company explores delivering products more through
the pharmacy channel. "A lot [is] cooking," Dianaty said.
"And I would expect that over the next three to five years,
the innovation is going to continue because this market is
ready for it and wants it."
www.medtronic-diabetes.co.uk
YpsoMed
The mylife YpsoPump is a small and lightweight insulin
pump which is easy and intuitive to use. With the new
mylife Assist app, you can experience app-based diabetes
management on your smartphone. If you are already a
user, update your mylife app. The new feature integrates
the Dexcom G6 Continuous Glucose Monitoring (CGM)
System with the mylife YpsoPump system. Your relevant
therapy data is available at a glance on your smartphone,
from glucose readings to insulin data.
The mylife app is also able to calculate bolus
suggestions based on CGM values. It's possible to
configure alerts when the values are high or low. Coming
soon is an easy share option for your CGM data to be
seen by any of your followers who are using the Dexcom
Follow2 app.
It is not complicated to setup, and you don't have
to change your insulin pump. A setup assistant guides
you through setting up the Dexcom G6 system. The
app-based approach of diabetes management allows for
ongoing development and improvement of the system.
There will be free and regular mylife app updates.
Download for free from the Google Play Store and, as
soon as it's available, from the Apple App Store.
Ypsomed's mylife Assist is part of the company's
mylife Loop3 development program which will be
introduced as three steps of app-based features. The
next app is the mylife Dose3 feature, which offers you
the ability to bolus via the mylife YpsoPump directly
from your smartphone. The final step of the Loop3
development programe is mylife Loop3, the planned
integration of automated insulin delivery (AID).
www.mylife-diabetescare.co.uk
RESOURCES
Businesswire
Drug Delivery Business
Medtechdive